Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency

  • Ganesh Raghu*
  • , Marya Ghazipura
  • , Thomas R. Fleming
  • , Kerri I. Aronson
  • , Jürgen Behr
  • , Kevin K. Brown
  • , Kevin R. Flaherty
  • , Ella A. Kazerooni
  • , Toby M. Maher
  • , Luca Richeldi
  • , Joseph A. Lasky
  • , Jeffrey J. Swigris
  • , Robert Busch
  • , Lili Garrard
  • , Dong Hyun Ahn
  • , Ji Li
  • , Khalid Puthawala
  • , Gabriela Rodal
  • , Sally Seymour
  • , Nargues Weir
    • Sonye K. Danoff, Neil Ettinger, Jonathan Goldin, Marilyn K. Glassberg, Leticia Kawano-Dourado, Nasreen Khalil, Lisa Lancaster, David A. Lynch, Yolanda Mageto, Imre Noth, Jessica E. Shore, Marlies Wijsenbeek, Robert Brown, Daniel Grogan, Dorothy Ivey, Patrycja Golinska, Banu Karimi-Shah, Fernando J. Martinez
*Corresponding author for this work

Research output: Contribution to journal › Conference article › Academic › peer-review

60 Citations (Scopus)
11 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency'. Together they form a unique fingerprint.

Medicine and Dentistry